Merck said FDA has extended the action date for the supplemental Biologics License Application for Keytruda as monotherapy for the first-line treatment of locally advanced or metastatic NSCLC in patients whose tumors express PD-L1 (tumor proportion score [TPS] ≥1%) without EGFR or ALK genomic tumor aberrations.
The Cancer Letter’s most recent cover story featured an in-depth Q&A with Anthony G Letai, director of the National Cancer Institute.
